AIkido Pharma Inc. (Nasdaq: AIKI) announced on July 31, 2020, that it has regained compliance with the NASDAQ's minimum bid price requirement of $1.00. The company met this requirement by maintaining a closing bid price of at least $1.00 for ten consecutive business days. This development supports AIkido's continued presence on the NASDAQ Capital Market, important for its operational stability and investor confidence.
AIkido Pharma Inc. (Nasdaq: AIKI) announced progress in identifying antiviral compounds aimed at combating COVID-19. Following an April 2020 agreement with the University of Maryland, researchers discovered a human protein complex linked to virus replication. Using a method called SILCS, they found compounds that inhibit various viruses, including COVID-19 and Influenza. CEO Anthony Hayes emphasized the role of machine learning in accelerating drug research, ultimately aiming to develop compounds that effectively treat multiple viral infections.
AIkido Pharma Inc. (Nasdaq: AIKI) provided an update on its machine learning-driven pancreatic cancer research, identifying 100 candidate markers associated with the disease. In collaboration with The University of Texas Southwestern Medical Center and Cogia BioTech, the Company aims to enhance diagnostic procedures and tailor drug treatments for patients. CEO Anthony Hayes emphasized the significance of machine learning in oncology drug development. AIkido also develops therapies for various cancers and a broad-spectrum antiviral platform targeting multiple viruses.